IP Verse

Dosing Regimen For Anti-Bcma Agents

Patent No. EP4058148 (titled "Dosing Regimen For Anti-Bcma Agents") was filed by Amgen on May 8, 2020. The application was issued on Mar 13, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ABBVIEDec 13, 2024KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF
REGENERON PHARMACEUTICALSAug 2, 2024CARPMAELS & RANSFORD
STRAWMANMar 15, 2024RCF PROTECTING INNOVATION

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP4058148

AMGEN
Application Number
EP20729951A
Filing Date
May 8, 2020
Status
Granted And Under Opposition
Feb 9, 2024
Publication Date
Mar 13, 2024
External Links
Slate, Register , Google Patents